We use cookies to improve your experience on this website. Read More Allow Cookies

Latest News From BioPharmaChem

    November 2016

  • Genomics Medicine Ireland Raises €40m, to Create 150 Jobs

    01 November, 2016

    A clinical trial has been proposed to take place in Ireland. The trial will be conducted through a subsidiary of Amgen called deCode based in Iceland. The clinical trial will study the relationship between genetics and disease. The study will focus on diseases such as Alzheimer’s and multiple sclerosis to find potential treatments for these diseases. This will be a significant contribution to the field of genetic therapy.

    Continue Reading »

  • Pharma Firm PPD Set to Add 50 New Jobs in Athlone

    02 November, 2016

    A pharmaceutical company based in Athlone, Co. Westmeath is set to deliver 50 new jobs. Pharmaceutical Product Development (PPD) has expanded its facility in Athlone and when the expansion is finished, 200 individuals will be employed by the company in Ireland. This facility was opened in 2010 and this expansion shows the companies interest in operating in Ireland. PPD is a contract laboratory that aids in the development of pharmaceutical products. They can help with drugs in pre-clinical, clinical trials as well as help with products that have made it onto the market. The company has the capability to meet very complex development projects and specialises in bioanalytical, biomarkers, central lab, GMP and vaccine sciences.

    Continue Reading »

  • Irish Start-up Nuritas Leads Fight to Prevent Diabetes

    04 November, 2016

    Diabetes has been named by the World Health Organisation as an epidemic with 422 million people having the disease in the world. An Irish start up organization has gained funding to produce a supplement to prevent pre-diabetes. Pre-diabetes is a condition where the glucose levels inn a persons body are much higher than normal. Patients with Pre-diabetes run a high chance of developing type-2 diabetes. Nuritas has discovered a peptide that could potentially prevent people who have pre-diabetes from going on to develop full-blown diabetes. The start-up received funding from the 2020 Horizon incentive. This will help to combat this epidemic and hopefully lower the number of people get type 2 diabetes.

    Continue Reading »

  • Alzheimer’s Breakthrough Possible as ‘Switch-Off’ Drug Identified

    07 November, 2016

    A new Alzheimer's drug being developed by Merck could potentially be used to slow down the progression of the disease. It will also prevent the build up of plaque in the brain of the individual. The plaque that builds up in the brain is thought to build up on healthy neurons and to stop them from working. The new drug will prevent this plaque from being produced and will. In the clinical trial 32 patients with early stage, Alzheimer's disease were treated with the drug as well as healthy volunteers. It is sill early days however if the drug is fit for the market then it will be the first Alzheimer's drug produced in a decade. This is fantastic news for patients living with this condition

    Continue Reading »

  • Kinesis Health Technologies, the Creator of Devices that Prevent Falls in Older People, has Raised €590,000 to Expand Global Sales.

    09 November, 2016

    Kinesis Health Technologies, the manufacturer of technology that is capable of alerting attendants if an elderly patient has fallen. As people age they are more and more likely to have a fall due to the deterioration of balance, mobility and muscle strength. These falls could cause an elderly patient to be hospitalised for a long period of time and could cause them to lose their independence. The company manufacture a device that can be used to estimate how likely a patient is of falling and hurting themselves. This can be done easily by carrying out tests and they can also have wireless sensors which can be attached to protect patients that are at risk of falling. This company has received private investment to extend its manufacturing capabilities and to expand the range of products that they produce.

    Continue Reading »

  • Abbott Develops Star Trek-Like Device to Lessen Pain of Diabetes Readings

    11 November, 2016

    Med Tech Giant Abbott has developed a new device that can measure the glucose content of blood without having to prick your finger for blood. The Freestyle Libre sensor can be attached to the lower back or the arm to give a real-time measure of the glucose content in a patient's blood. The sensor does not require the patient to extract blood to work take the measurement. The device can keep track of the glucose levels over a period of 90 days which will allow them to see how they are doing overall. It is a fantastic innovation for diabetes care and the device is available commercially in Ireland now.

    Continue Reading »

  • Chanelle’s Global Innovation Award

    13 November, 2016

    Chanelle, a generic animal drug manufacturer, won the pharma industry award for Pharma Project of the Year 2016. The drug, Rheumocam, can be used to treat rheumatoid conditions in horses. Before the development of this generic drug, the API was produced as an injectable solution. This made it difficult to administer because the horse had to be handled by the owner. Rheumocam on the other hand was developed as a powder.The powder can be spread on the horses food. They even made the drug to taste like apples making it more delectable to the horse. What a great innovation.

    Continue Reading »

  • Skillnets Statement of Strategy launched

    Skillnets Statement of Strategy launched

    15 November, 2016

    Skillnets launched their Statement of Strategy 2016-2019 on November 3rd, 2016. Skillnets Statement of Strategy and ensuring goals are closely aligned with national policy and will contribute to the implementation of national workforce development aims as highlighted in Ireland's National Skills Strategy 2025.

    Continue Reading »

  • Genzyme Ireland Profits Rise to €68.5m

    18 November, 2016

    Genzyme is a company that produce orphan drugs. Orphan drugs are those which are used to treat chronic diseases. Chronic diseases affect a patient on a daily basis. Orphan drugs are produced for conditions that only affect a very small number of people in the population. In Genzyme, Waterford drugs are produced to treat inherited disorders, kidney disease and immune diseases. The company has made a profits rise last year to € 68.5m. 

    Continue Reading »

  • Amryt Pharma gets US Patent for Headline Drug

    21 November, 2016

    Amryt Pharma has been given a U.S. patent to start phase III studies of their drug in the U.S. The drug, Episalvan, is being developed to help with an orphan disease (see the previous post to learn more about orphan drugs and diseases) called epidermolysis bullosa (EB) and partial-thickness wounds. The company specialises in the development of novel treatments for patients suffering from orphan diseases. They have two other products currently in their pipeline. One of these drugs is to help patients with Cushing's disease. Prospects are looking up for this company as they move into 2017.

    Continue Reading »

  • A Very Healthy Sector as Growth Acts as Magnet for More Investment

    23 November, 2016

    The Medtech industry is booming in Ireland. This is because of well-executed planning from IDA Ireland. The production of a Medtech hub in Galway has attracted the giants of this industry to Ireland. At the moment 13 of the top 15 Medtech companies are based in Ireland. The foundation of Cúram as an institute attached to NUIG Galway further strengthens this hub and will make it more attractive towards medical Device manufacturers.

    Continue Reading »

  • Irish Researcher Awarded €8.8m to Develop Inhaler for Lung Disease

    24 November, 2016

    A researcher from Trinity college has gained a large investment to produce an inhaler for use in the treatment of Cystic Fibrosis. Cystic Fibrosis is where mucus builds up in the lungs of the individual, obstructing the breathing airways. Patients also have a higher chance of getting chest infections which can lead to other serious repercussions. The drug is being developed to break up the mucus which builds up in the lungs. This will free up the airway and will allow the patient to breathe again. The great thing about using an inhaler to deliver the drug is that the drug will be administered directly to the part of the body where it is needed, the lungs. This will ensure that more of the drug will make it to the lungs to break up the mucus.

    Continue Reading »

  • Enda Kenny Launches "Game Changing" €86m Bernal Institute at UL

    28 November, 2016

    The Bernal Research institution has opened up in conjunction with Limerick University. The institute will conduct research in the Engineering and Science fields. It was established through a collaboration between industry, higher education and industry. The state-of-the-art facility will hold 260 researchers who will focus on the following research areas: Advances in pharmaceuticals, medicines and materials science.

    Continue Reading »